NDEL1

Across TCGA pan-cancer cohorts, NDEL1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NDEL1 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NDEL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NDEL1 expression acts as an unfavorable survival marker.

STAD, PRAD, and UCEC are the cancer types where NDEL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.097	0.667	<.001	6	view →
PRAD	DFS	Median	All	0.068	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	All	0.174	0.625	.023	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
COAD	DFS	Median	II,III,IV	0.208	0.648	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NDEL1–STAD (OS)

Open the STAD breakdown →